文献速递白血病造血干细胞移植与细胞治疗

移植前使用多种酪氨酸激酶抑制剂对慢性髓性白血病异基因造血干细胞移植结局的临床影响

Clinical impact of pretransplant use of multiple tyrosine kinase inhibitors on the outcome of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia.
PubMed 文献 · Am J Hematol · 2017-06-09

该研究分析237例移植前接受1至3种酪氨酸激酶抑制剂(TKI)治疗的慢性期慢性髓性白血病(CML-CP)患者,其中153例用1种、49例用2种、35例用3种TKI。移植前使用3种TKI被确定为预后的显著不良因素,且非复发死亡率高于使用1种或2种TKI者。作者认为,对二线TKI治疗耐药且有合适供者的年轻CML-CP患者可考虑异基因造血干细胞移植。

要点

  • 移植前使用3种TKI是CML-CP患者异基因造血干细胞移植预后的显著不良因素。
  • 使用3种TKI的患者非复发死亡率高于使用1种或2种TKI的患者。
  • 作者认为,对二线TKI耐药且有合适供者的年轻CML-CP患者可考虑异基因造血干细胞移植。

核心结论

  • 移植前使用3种TKI被确定为CML-CP患者异基因造血干细胞移植预后的显著不良因素。
  • 作者认为,对二线TKI治疗耐药且有合适供者的年轻CML-CP患者可考虑异基因造血干细胞移植。

研究设计与样本

  • 研究纳入237例移植前接受1至3种TKI治疗的CML-CP患者,其中153例用1种、49例用2种、35例用3种TKI。

主要发现

  • 除移植时疾病状态和患者年龄等常规危险因素外,移植前使用3种TKI被确定为预后的显著不良因素。
  • 使用3种TKI的患者非复发死亡率高于使用1种或2种TKI的患者。

临床怎么用

  • 作者认为,对二线TKI治疗耐药且有合适供者的年轻CML-CP患者可考虑异基因造血干细胞移植。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tyrosine kinase inhibitors (TKIs) are widely used to treat patients with chronic myelogenous leukemia in the chronic phase (CML-CP), and outcomes of TKI treatment for patients with CML-CP have been excellent. Since multiple TKIs are currently available, second-line or third-line TKI therapy is considered for patients who are intolerant of or resistant to the previous TKI treatment. Therefore, allogeneic hematopoietic stem cell transplantation (allo-HSCT) is considered only for patients with disease progression or for patients after treatment failure with multiple TKIs. To reflect the current clinical situation of patients with CML-CP, we tried to clarify whether prior TKI treatment affects the outcome of allo-HSCT. Data from 237 patients for whom the number of pretransplant TKIs varied from one to three were used for analysis. Before allo-HSCT, 153 patients were treated with one TKI, 49 patients were treated with two TKIs and 35 patients were treated with three TKIs. In addition to conventional risk factors, i.e., disease status at transplantation and patient's age, the use of three TKIs before transplantation was identified as a significant adverse factor for prognosis. Nonrelapse mortality rate was higher in patients treated with three TKIs than in patients treated with one or two TKIs. Our results suggest that allo-HSCT could be considered for young patients with CML-CP who manifest resistance to second-line TKI therapy and who have an appropriate donor.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Kondo T, Nagamura-Inoue T, Tojo A, et al. Clinical impact of pretransplant use of multiple tyrosine kinase inhibitors on the outcome of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia. Am J Hematol. 2017. PMID: 28543934. doi:10.1002/ajh.24793

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。